





The Patent Office
Concept House
Cardiff Roadjul 2003
Newport
SpwipWales FCT
NP10 800

I, the undersigned, being an officer duly authorised in accordance with Section74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the international application filed on 19 June 2002 under the Patent Cooperation Treaty at the UK Receiving Office. The application was allocated the number PCT/GB2002/002814.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Date:

27 May 2003

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

An Executive Agency of the Department of Trade and Industry

BEST AVAILABLE COPY



Original (for SUBMISSION) - printed on 19.06.2002 02:31:04 PM

PG4501A

0	For receiving Office use only				
0-1	International Application No.	PC7/GB 02/02514			
0-2	International Filing Date	19 JUNE 2002 1910/1900			
0-3	Name of receiving Office and "PCT	19/06/2002			
	International Application"	United Kingdom Patent Office			
_		PCT International Application			
		AND THE PROPERTY OF THE PROPER			
0-4	Form - PCT/RO/101 PCT Request				
0-4-1	Prepared using	PCT-EASY Version 2.92			
		(updated 01.01.2002)			
0-5	Petition	(updated 01.01.2002)			
	The undersigned requests that the	•			
	present international application be processed according to the Patent				
	Cooperation Treaty				
0-6	Receiving Office (specified by the applicant)	United Kingdom Patent Office (RO/GB)			
0-7	Applicant's or agent's file reference	PG4501A			
1	Title of invention	COMPOUNDS			
11	Applicant	- COLL CONDS			
()-1	This person is:	applicant only			
11-2	Applicant for	1 · · · · · · · · · · · · · · · · · · ·			
11-4	Name	all designated States except US GLAXO GROUP LIMITED			
11-5	Address:				
		Glaxo Wellcome House			
		Berkeley Avenue Greenford, Middlesex UB6 ONN			
	1	United Kingdom			
11-6	State of nationality	GB			
11-7	State of residence	GB			
11-8 ·	Telephone No.	.020 8047 5000			
11-9	Facsimile No.	020 8047 6894			
111-1	Applicant and/or inventor	020 .0047 8894			
III-1-1	This person is:	annligant and income			
III-1-2	Applicant for	applicant and inventor US only			
111-1-4	Name (LAST, First)	KING, Paula			
III-1-5	Address:	GlaxoSmithKline			
		Park Road			
		Ware, Hertfordshire SG12 ONY United Kingdom			
111-1-6	State of nationality	GB			
111-1-7	State of residence	GB .			





PC 02/02814

PG4501A

Original (for SUBMISSION) - printed on 19.06.2002 02:31:04 PM

III-2 Applicant and/or inventor	
III-2-1 This name is	
III-2-2 Applicant for applicant and inventor US only	
111 2 4 No 4 ACT = 11	•
BICKLES, Barry, Riddle	
GlaxoSmithKline	
Five Moore Drive	
Research Triangle Park, NC 27709	
United States of America US United States of III-2-6	
III-2-7 State of residence US	
IV-1 Agent or common representative: or	
address for correspondence	
The person identified below is hereby/has been appointed to act on	
behalf of the applicant(s) before the	
competent International Authorities as: IV-1-1 Name (LAST, First)	
GIDDINGS, Peter, John	
GlaxoSmithKline	
Corporate Intellectual Property	
(CN925.1)	
980 Great West Road	
Brentford, Middlesex TW8 9GS	
United Kingdom IV-1-3 Telephone No.	
020 8047 5000	
V Designation of States 020 8047 6894	
V.1 Decirio Del	
(other kinds of protection or treatment AP: GH GM KE LS MW MZ SD SL SZ TZ	UG ZM
if any, are specified between ZW and any other State which is a parentheses after the designation(s) Contracting State of the Hamman	
concerned) Contracting State of the Harare Pr and of the PCT	otocol
EA: AM AZ BY KG KZ MD RU TJ TM and	any
other State which is a Contracting	State
of the Eurasian Patent Convention a	and of
EP: AT BE CHELI CY DE DK ES FI FR	TP CD
IE IT LU MC NL PT SE TR and any oth	SD GR
State which is a Contracting State	of
the European Patent Convention and	of
the PCT	
OA: BF BJ CF CG CI CM GA GN GQ GW N	IL MR
NE SN TD TG and any other State whi	ch is
a member State of OAPI and a Contra	cting
State of the PCT	



Original (for SUBMISSION) - printed on 19.06.2002 02:31:04 PM

PG4501A

V-2			
V-Z	National Patent (other kinds of protection or treatment	AE AG AL AM AT AU	Z BA BB BG BR BY BZ
	If any, are specified between	CA CHELI CN CO CR C	CU CZ DE DK DM DZ EC
	parentheses after the designation(s) concerned)		H GM HR HU ID IL IN
	oncerned)	IS JP KE KG KP KR K	
		LV MA MD MG MK MN M	
		DT DE	
		TR TT TZ HA HC HE H	Z VN YU ZA ZM ZW
V-5	Precautionary Designation Stateme	nt	- 11 10 2A 2M ZW
-	In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b all designations which would be permitted under the PCT except any designation(s) of the State(s) Indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant		
V-6	at the expiration of that time limit.		
. V-0	Exclusion(s) from precautionary designations	NONE	
VI-1	Priority claim of earlier national		
VI-1-1	application Filing date		
VI-1-2		20 June 2001 (20.06.	2001)
VI-1-3	•	0115178.6	
VI-2	Priority document request	GB	•
- VOI	The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):	VI-1	
VII-1	International Searching Authority Chosen	European Patent Offi	ce (EPO) (ISA/EP)
VIII	Declarations	Number of declarations	(===, (===, ==)
VIII-1	Declaration as to the identity of the inventor	- Transcript declarations	
VIII-2	Declaration as to the applicant's		
	entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's	_ :	
	entitlement, as at the international filing date, to claim the priority of the earlier		
	application		
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	_	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	_	
IX	Check list	number 6 1	
IX-1	Request (including dealers (including	number of sheets 4	electronic file(s) attached
IX-2	Donorietia	5	<u> </u>
IX-3	Claims	4	_
IX-4	Abotest	•	
IX-5	Drawings		EZABST00.TXT
IX-7	TOTAL	14	-
		* T	

PL REQUEST



Original (for SUBMISSION) - printed on 19.06.2002 02:31:04 PM

PG4501A

•	Accompanying items	paper document(s) attached		electronic file(s) attached	
IX-8	Fee calculation sheet	<u> </u>	√	-	
IX-17	PCT-EASY diskette .			Diskette	
IX-19	Figure of the drawings which should accompany the abstract				
IX-20 ⁻	Language of filing of the international application	English	0.0		
X-1	Signature of applicant, agent or common representative			<u>)</u>	
X-1-1	Name (LAST, First)	GIDDINGS,	Peter, Joh	<u></u>	

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	19	JUNE	2002	19/06/2002	
10-2	Drawings:	<u> </u>				
10-2-1	Received ✓					
10-2-2	Not received			•		
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application		•			
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)					
10-5	International Searching Authority	ISA/E	?			
10-6	Transmittal of search copy delayed until search fee is paid					

FOR INTERNATIONAL BUREAU USE ONLY

		·
11-1	Date of receipt of the record copy by	
	the International Bureau	
		<u> </u>

30

Compounds

The present invention relates to heterocyclyl substituted adenosine derivatives. More particularly the invention is concerned with a particular physical form of (2S,3S,4R,5R)-2-(5-tert-butyl-

- 5 [1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol, pharmaceutical formulations thereof and its use in therapy.
 - WO99/67262 (Glaxo Group Limited) discloses certain heterocyclyl adenosine derivatives including (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-
- fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol, Example 14 of WO99/67262, the structure of which is indicated below as the compound of formula (A):

(A)

- The preparation of the compound of formula (A) is described in WO99/67262. The compound of formula (A) may be prepared by the reaction of 4-chloro-2-fluoroaniline with an appropriate purinyl derivative having a suitable leaving group in the 6-position of the purine ring, optionally in the presence of a solvent at elevated temperatures. Alternatively the compound of formula (A) may be prepared by treating 9-{(3aR,4R,6S,6aR)-6-[5-tert-butyl-1,3,4-oxadiazol-2-yl]-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-vl}-N-(4-chloro-2-fluorophenyl)-9H-purin-6-amine
- dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl}-N-(4-chloro-2-fluorophenyl)-9H-purin-6-amine with trifluoroacetic acid followed by treatment with sodium bicarbonate. Extraction of the product into ethyl acetate followed by evaporation in vacuo provides the compound of formula (A) as a buff solid.
- We have now surprisingly found that the compound of formula (A) can be obtained in polymorphic forms.
 - There is thus provided as a first aspect of the invention (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form.

(

5

15

20

30

35

40

We have found that the compound of formula (A) may be obtained by crystallisation under certain conditions in the form of polymorphic form I (hereinafter Polymorph I).

There is thus provided in a further aspect of the invention (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol as Polymorph I.

Polymorph I exhibits particular stability at ambient temperatures, for example 15-20°C.

Polymorph I is easy to handle and particularly easy to process on a large scale and thus is useful in the preparation of pharmaceutical formulations.

In a preferred aspect the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph I as herein defined substantially free of any other polymorph.

In a further preferred aspect the invention (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph I as herein defined substantially free of impurities.

By "substantially free" is meant containing less than 10%, preferably less than 5%, more preferably less than 2%, of alternative polymorph or impurity.

(2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol may be prepared in polymorphic form by crystallisation of the compound under suitable conditions.

Polymorph I may be prepared substantially free from alternative polymorph by controlling crystallisation conditions.

In general, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph I may be obtained by crystallisation of the compound by heating in N,N-dimethylformamide at a temperature sufficient to effect dissolution, for example 70-90°C, initiating crystallisation by controlled addition of water until turbidity results, and allowing to cool to ambient temperature, for example 15-25°C.

Alternatively, Polymorph I is obtained by dissolving (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in N,N-dimethylformamide/water in a ratio of 3.5:1 to 2.5:1, preferably 3:1, optionally treating with decolourising charcoal, and cooling to less than 30°C, preferably 20-25°C, adding water and stirring the slurry prior to collecting the solid.

10

20

30

In a further alternative preparation Polymorph I may be prepared by dissolving (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in N,N-dimethylformamide and water wherein the N,N-

- dimethylformamide:water ratio is from 3.5:1 to 2.5:1, optionally treating with decolourising charcoal, and either cooling to less than 25°C or cooling to less than 30°C and seeding with polymorph I; and optionally adding toluene prior to collection of the solid.
 - Interconversion of one polymorph to another can occur under certain circumstances.

The methods for the preparation of polymorphic material, and in particular methods for the preparation of Polymorph I, described herein constitute further aspects of the present invention.

Polymorph I has been characterised by X-ray powder diffraction (XRPD) studies and Raman spectroscopy.

Polymorph I is characterised by having peaks in its Raman spectra at 3429, 3414 and 76 cm⁻¹.

Raman peaks are quoted to the nearest cm-1.

Polymorph I is characterised by having an XRPD pattern with signals at 4.32, 4.99, 6.23, 6.97, 8.64, 10.04, 12.53, and 14.47 (degrees 2-theta).

The skilled person will recognise that XRPD peak positions are affected by differences in sample height. The peak positions quoted herein are thus subject to a variation of +/- 0.15 degrees 2-theta.

This invention further provides for a pharmaceutical composition comprising (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form, and a pharmaceutically acceptable carrier and/or excipient.

Suitable pharmaceutically acceptable carriers and excipients are described in WO 99/967262.

- 35 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form may be used for decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea, as described in WO 99/67262.
- 40 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form may be used in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or

treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea, as described in WO 99/67262.

WO 99/67262 (Glaxo Group Limited) is incorporated by reference herein as though fully set forth.

The following examples illustrate the invention but are not intended as a limitation thereof.

10

15

5

EXAMPLES

(2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol was prepared according to the methods described in WO99/67262.

Example 1 - Preparation of Polymorph I

(2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol (1g) was taken up in N,N-dimethylformamide (DMF, 5mL) and the mixture heated to 70°C to effect dissolution. Water was added at this temperature until tubidity occurred (5mL). The solution was then cooled to ambient (crystallisation ensued at ca. 50°C) and allowed to stand for 1 hour before being filtered and the solid washed with water (1x2mL). The wet cake was dried in vacuo at ambient temperature. Yield: 85%.

Example 2 - Preparation of Polymorph I

(2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol (20.0g) was dissolved in 3:1 DMF/water (266mL), decolourising charcoal (5.0g) added and the suspension heated at 60°C for 1 hour. The charcoal was removed by filtration, the filter washed with 3:1 DMF/water (88mL) and the filtrate cooled to 22-25°C. Water (44mL) was added at 22-25°C and the slurry stirred overnight. Water (132mL)
 was added, stirring continued for 2 hours and the product collected by filtration, washed consecutively with aqueous DMF and water and then dried *in vacuo* at 40°C to give Polymorph I as an off white solid (16.3g, 81% recovery).

40 X-Ray Powder Diffraction

The sample preparation and acquisition conditions were as follows:

Samples were lightly ground and packed into silicon cup with a 12 mm (diameter) x 0.5 mm cavity. Data were acquired using a Bruker D8 Advance X-Ray diffractometer configured with a Cu anode, primary and secondary Soller slits, secondary monochromator and scintillation counter. The generator was operated at 40 kV 40 mA. Variable divergence and antiscatter slits were set at 12 mm irradiated area, and the detector slit was set at 0.1 mm. A locked coupled step scan with 0.02 degrees 2 -theta step was used. The sample was rotated.

Data obtained for Polymorph I are shown in Figure I.

10

15

5

Raman Spectroscopy

Raman spectra were acquired using a Nicolet 960 ESP FT-Raman spectrometer. Samples were held in glass vials; spectra of 5 different points on a sample were averaged. Data collection parameters include: Laser power: 400 mW, Resolution: 4 cm⁻¹, Sample gain: 1.0, Detector: InGaAs, Beamsplitter: CaF2, Correction: none, Zero filling: none, Apodization: Happ-Genzel, Phase correction: Power spectrum.

A Raman spectrum of Polymorph I are shown in Figure 2.

20

25

A photographic image of Polymorph I is shown in Figure 3.

The application of which this description and these claims form a part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features relating to the invention described herein. They may take the form of product, process or use claims and may include, by way of example and without limitation, the claims that follow.

CLAIMS

5

15

20

- 1. (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form.
- 2. A polymorphic form according to claim 1 wherein the polymorphic form is Polymorph I.
- 3. A pharmaceutical formulation comprising a polymorphic form according to claim 1 or claim 2, and a pharmaceutically acceptable carrier and/or excipient.
 - 4. A polymorphic form according to claim 1 or claim 2 for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea.
 - 5. Use of a polymorphic form according to claim 1 or claim 2 in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea.
 - 6. (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form substantially as described herein in the specification and/or examples.

(

5

ABSTRACT

(2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form.

Figure 1

X-RAY DIFFRACTION DATA

5 Polymorph I

GW493838 1A05583 DB100065-003A0




Figure 2

5

RAMAN SPECTRA


Polymorph I

25

20

5

Figure 3
PHOTOGRAPHIC IMAGE OF POLYMORPH I



Form I Aqueous DMF

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
MAGE CUT OFF AT TOP, BOTTOM OR SIDES
✓ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
Потить

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.